Tan, Y.; Xiao, C.; Wang, Z.; Kong, Y.; Huang, Y.; Liu, Z.; Wu, Q.; Wu, C.; Zhao, M.; Chen, J.;
et al. Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma. Pharmaceuticals 2026, 19, 47.
https://doi.org/10.3390/ph19010047
AMA Style
Tan Y, Xiao C, Wang Z, Kong Y, Huang Y, Liu Z, Wu Q, Wu C, Zhao M, Chen J,
et al. Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma. Pharmaceuticals. 2026; 19(1):47.
https://doi.org/10.3390/ph19010047
Chicago/Turabian Style
Tan, Yinhua, Chunxiu Xiao, Zhifan Wang, Yuhang Kong, Yamei Huang, Zhichang Liu, Qiang Wu, Chenyu Wu, Manyu Zhao, Jingyao Chen,
and et al. 2026. "Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma" Pharmaceuticals 19, no. 1: 47.
https://doi.org/10.3390/ph19010047
APA Style
Tan, Y., Xiao, C., Wang, Z., Kong, Y., Huang, Y., Liu, Z., Wu, Q., Wu, C., Zhao, M., Chen, J., & Xiao, K.
(2026). Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma. Pharmaceuticals, 19(1), 47.
https://doi.org/10.3390/ph19010047
